


# ABOUT PARP

PARP enzymes and BRCA proteins are responsible for DNA replication and cell survival. Tumor cells with a *gBRCA* mutation are dependent on PARP and other repair proteins for DNA repair.<sup>6,7</sup>



**References:** **6.** Gavande NS, VanderVere-Carozza PS, Hinshaw HD, et al. DNA repair targeted therapy: the past or future of cancer treatment? *Pharmacol Ther.* 2016;160:65-83. **7.** Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. *BMC Med.* 2015;13:188. doi:10.1186/s12916-015-0425-1. **8.** Shao G, Lilli DR, Patterson-Fortin J, Coleman KA, Morrissey DE, Greenberg RA. The Rap80-BRCC36 de-ubiquitinating enzyme complex antagonizes RNF8-Ubc13-dependent ubiquitination events and DNA double strand breaks. *Proc Natl Acad Sci U S A.* 2009;106(9):3166-3171. **9.** Lee JM, Ledermann JA, Kohn EC. PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. *Ann Oncol.* 2014;25(1):32-40. **10.** Lupo B, Trusolino L. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. *Biochim Biophys Acta.* 2014;1846(1):201-215. **11.** Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. *Nat Rev Cancer.* 2010;10(4):293-301. doi:10.1038/nrc2812.